Lixte Biotechnology Holdings, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: East Setauket NY United States (2006)

Organization Overview

First Clinical Trial
2013
NCT01837667
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Lixte Biotechnology Holdings, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

lb-100 (2 trials)

Drugs in Phase 1 Trials (1)

docetaxel (taxotere) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Myelodysplastic Syndromes (Phase 2)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2